Type 1 diabetes mellitus

15 trials 4 recruiting MedDRA PT
15 Registered trials
4 Recruiting
14 Unique sponsors
18 Unique IMPs
7 Commercial trials
Drug classes (ATC)
— ATC code not specified 7
N Neurology/Psychiatry (ATC N) 2
R Respiratory (ATC R) 1
M Musculoskeletal (ATC M) 1
L Oncology (ATC L) 2
C Cardiology (ATC C) 3
Mechanism of action (INN-stem analysis)
Unknown / small molecule 13 substances
Analgesic / antipyretic 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Fibrate 1 substance
Receptor fusion protein 1 substance
Calcineurin inhibitor 1 substance
Phase III: 1 Phase II: 11 Phase I/II: 1 Phase I (Other): 1 Phase I (First in Human): 1

Filter these 15 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 15 trials

Phase III

1 trial

Phase II

11 trials
  • Diamyd Medical AB Commercial
    GLUTAMATE DECARBOXYLASE 2, HUMAN, RECOMBINANT
    2024-513350-30-00 1 country 2024 n=16
    Ended
  • Dompe' Farmaceutici S.p.A. Commercial
    LADARIXIN
    2024-513560-26-00 3 countries 2020 n=103
    Ended
  • Itb-Med AB Commercial
    CETIRIZINE DIHYDROCHLORIDE; PARACETAMOL; SIPLIZUMAB
    2023-506837-31-00 4 countries 2023 n=113
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    IMP not specified
    2022-500531-36-00 13 countries 2024 n=284
    Recruiting
  • Gentofte Hospital Academic
    COLCHICINE
    2022-502038-23-00 1 country 2023
    Ended
  • Institute For Clinical And Experimental Medicine Academic
    ANTI-T LYMPHOCYTE IMMUNOGLOBULIN FOR HUMAN USE, RABBIT
    2023-508514-42-00 1 country 2024 n=18
    Recruiting
  • Medical University Of Graz Academic
    VERAPAMIL HYDROCHLORIDE
    2023-506545-27-01 5 countries 2025 n=64
    Ended
  • Medical University Of Graz Academic
    VERAPAMIL HYDROCHLORIDE; VERAPAMIL HYDROCHLORIDE PH. EUR.
    2024-515234-33-00 5 countries 2024 n=19
    Ended
  • Medical University Of Lodz Academic
    LISDEXAMFETAMINE DIMESYLATE; METHYLPHENIDATE HYDROCHLORIDE
    2023-506862-30-00 1 country 2024 n=150
    Recruiting
  • Medical University Of Warsaw Academic
    FENOFIBRATE MICRONISED
    2024-517483-34-00 1 country 2022 n=98
    Ended
  • Ospedale San Raffaele S.r.l. Academic
    LADARIXIN
    2025-524298-18-00 1 country n=46
    Not authorised

Phase I/II

1 trial
  • Centre Hospitalier Universitaire De Nantes Academic
    ANAKINRA; ETANERCEPT; MYCOPHENOLIC ACID; TACROLIMUS
    2025-524834-24-00 1 country n=15
    Pending

Phase I (Other)

1 trial
  • Gan & Lee Pharmaceuticals USA Corp. Commercial
    IMP not specified
    2025-523052-32-00 1 country 2025 n=14
    Ended

Phase I (First in Human)

1 trial
  • Altheia Science S.r.l. Commercial
    IMMUNOSTEM
    2025-521304-21-00 1 country 2026 n=15
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Medical University Of Graz Academic 2 Phase II 0
Gan & Lee Pharmaceuticals USA Corp. Commercial 1 Phase I (Other) 0
Diamyd Medical AB Commercial 1 Phase II 0
Dompe' Farmaceutici S.p.A. Commercial 1 Phase II 0
Itb-Med AB Commercial 1 Phase II 0
Sanofi-Aventis Recherche & Developpement Commercial 1 Phase II 1
Bayer AG Commercial 1 Phase III 0
Altheia Science S.r.l. Commercial 1 Phase I (First in Human) 1
Gentofte Hospital Academic 1 Phase II 0
Institute For Clinical And Experimental Medicine Academic 1 Phase II 1
Medical University Of Lodz Academic 1 Phase II 1
Medical University Of Warsaw Academic 1 Phase II 0
Ospedale San Raffaele S.r.l. Academic 1 Phase II 0
Centre Hospitalier Universitaire De Nantes Academic 1 Phase I/II 0
New trials by year
2020
1
2022
1
2023
2
2024
6
2025
2
2026
1
← All indication landscapes